Renaissance Technologies - ALPINE IMMUNE SCIENCES INC ownership

ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 77 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of ALPINE IMMUNE SCIENCES INC
ValueSharesWeighting
Q3 2023$3,300
+0.5%
288,194
-9.7%
0.01%
+20.0%
Q2 2023$3,282
+28.7%
319,294
-3.3%
0.01%
+66.7%
Q1 2023$2,550
+4.2%
330,294
-0.8%
0.00%0.0%
Q4 2022$2,447
-99.9%
332,894
-7.2%
0.00%
-25.0%
Q3 2022$2,583,000
-23.6%
358,694
-9.7%
0.00%0.0%
Q2 2022$3,382,000
-2.3%
397,394
+2.9%
0.00%0.0%
Q1 2022$3,463,000
-35.3%
386,094
-0.1%
0.00%
-42.9%
Q4 2021$5,350,000
+26.7%
386,294
-2.4%
0.01%
+40.0%
Q3 2021$4,221,000
+17.5%
395,594
-0.9%
0.01%
+25.0%
Q2 2021$3,591,000
-14.6%
398,994
+0.5%
0.00%
-20.0%
Q1 2021$4,207,000
-27.2%
396,894
-13.5%
0.01%
-16.7%
Q4 2020$5,781,000
+69.2%
458,794
+18.0%
0.01%
+100.0%
Q3 2020$3,417,000
+56.7%
388,683
+73.0%
0.00%
+50.0%
Q2 2020$2,181,000
+469.5%
224,655
+68.7%
0.00%
Q1 2020$383,000
-22.0%
133,155
+4.2%
0.00%
Q4 2019$491,000
+10.3%
127,810
+13.7%
0.00%
Q3 2019$445,000
-0.4%
112,361
+5.7%
0.00%
Q2 2019$447,000
-32.1%
106,261
+10.8%
0.00%
-100.0%
Q1 2019$658,000
+105.0%
95,861
+9.8%
0.00%
Q4 2018$321,000
-55.6%
87,292
-23.6%
0.00%
-100.0%
Q3 2018$723,000
-58.4%
114,274
-48.9%
0.00%0.0%
Q2 2018$1,737,000
+114.4%
223,724
+120.9%
0.00%0.0%
Q1 2018$810,000
+7.1%
101,300
+50.1%
0.00%0.0%
Q4 2017$756,000
+25.4%
67,500
+29.9%
0.00%0.0%
Q3 2017$603,00051,9790.00%
Other shareholders
ALPINE IMMUNE SCIENCES INC shareholders Q2 2023
NameSharesValueWeighting ↓
FRAZIER MANAGEMENT LLC 2,571,450$32,400,0002.50%
Omega Fund Management, LLC 1,284,900$16,190,0002.43%
Avidity Partners Management LP 1,248,000$15,725,0000.51%
Samsara BioCapital, LLC 399,190$5,030,0000.51%
EcoR1 Capital, LLC 741,290$9,340,0000.50%
DAFNA Capital Management LLC 113,202$1,426,0000.42%
TIGER MANAGEMENT L.L.C. 137,728$1,735,0000.39%
Orbimed Advisors 3,070,955$38,694,0000.34%
SPHERA FUNDS MANAGEMENT LTD. 198,260$2,498,0000.22%
Artal Group S.A. 593,030$7,472,0000.16%
View complete list of ALPINE IMMUNE SCIENCES INC shareholders